Americans spend over $60 billion a year on discounted prescriptions through a little-known government program — and many don’t even realize it exists.
It’s called the 340B Drug Pricing Program, and while it’s growing fast, most people and providers aren’t benefiting as much as they could.
It’s called the 340B Drug Pricing Program, and while it’s growing fast, most people and providers aren’t benefiting as much as they could.
Here’s how it works — and how we can fix it:
What is 340B? Since 1992, the U.S. government has required drug manufacturers to offer 25–50% discounts on medications to qualifying health systems. Around 60% of Health systems are eligible for this program.
The growth: In 2023, 340B sales hit a record $66 billion, more than double what they were just four years ago.
The catch: To benefit, health systems must dispense drugs through their own in-house pharmacy or contract with a third party pharmacy. That often means added fees, complexity, and limited access for patients.
The result: Even with the boom, only 16% of all U.S. prescriptions go through 340B. That’s a massive missed opportunity — especially for patients who could benefit from lower drug prices or expanded community health services.
How RxLink helps health systems unlock more 340B savings:
- Shift prescriptions in-house. We provide turnkey solutions to auto-transfer 340B eligible medications to in-house pharmacies.
- Educate patients. We text patients real-time cost comparisons — making them aware of cost savings at hospital pharmacies over outside pharmacies.
- Free analysis. We analyze prescription flows and tailor Health System Pharmacy Growth programs at no upfront cost.